- Home
- PHGE vs NEUP Comparison
PHGE vs NEUP Comparison
Compare PHGE & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- NEUP
- Stock Information
- Founded
- PHGE 2015
- NEUP 1996
- Country
- PHGE Israel
- NEUP United States
- Employees
- PHGE N/A
- NEUP N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- NEUP
- Sector
- PHGE Health Care
- NEUP
- Exchange
- PHGE Nasdaq
- NEUP Nasdaq
- Market Cap
- PHGE 11.0M
- NEUP 12.7M
- IPO Year
- PHGE N/A
- NEUP N/A
- Fundamental
- Price
- PHGE $0.49
- NEUP $6.73
- Analyst Decision
- PHGE Strong Buy
- NEUP Strong Buy
- Analyst Count
- PHGE 1
- NEUP 1
- Target Price
- PHGE $15.00
- NEUP $21.00
- AVG Volume (30 Days)
- PHGE 278.8K
- NEUP 28.6K
- Earning Date
- PHGE 08-13-2025
- NEUP 08-15-2025
- Dividend Yield
- PHGE N/A
- NEUP N/A
- EPS Growth
- PHGE N/A
- NEUP N/A
- EPS
- PHGE N/A
- NEUP 0.00
- Revenue
- PHGE N/A
- NEUP $15,662,715.00
- Revenue This Year
- PHGE N/A
- NEUP N/A
- Revenue Next Year
- PHGE N/A
- NEUP N/A
- P/E Ratio
- PHGE N/A
- NEUP $2.19
- Revenue Growth
- PHGE N/A
- NEUP N/A
- 52 Week Low
- PHGE $0.34
- NEUP $2.90
- 52 Week High
- PHGE $3.86
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- PHGE 51.35
- NEUP N/A
- Support Level
- PHGE $0.34
- NEUP N/A
- Resistance Level
- PHGE $0.51
- NEUP N/A
- Average True Range (ATR)
- PHGE 0.05
- NEUP 0.00
- MACD
- PHGE 0.01
- NEUP 0.00
- Stochastic Oscillator
- PHGE 77.53
- NEUP 0.00
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.